There are no Focus articles on TKPYY.
at CNBC.com (Apr 9, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Apr 8, 2014)
Thu, Jun. 19, 9:16 AM
- Citing a failure to demonstrate a statistically significant improvement in overall survival (OS), Takeda Pharmaceutical Company Ltd (TKPYY) terminates its orteronel development program for prostate cancer. The firm's decision is not unexpected considering its disclosure in 2013 that an interim analysis of the results of the Phase 3 ELM-PC5 clinical trial showed that orteronel would be unlikely to meet its primary endpoint of OS compared to placebo.
Fri, May. 23, 2:39 PM
- Takeda Pharmaceuticals (TKPHF, TKPYY) yesterday was found not liable for the bladder cancer of two women who used its Actos diabetes medication, as a Nevada jury agreed with the company that the drug did not cause the women’s disease.
- A jury last month ordered Takeda and partner Eli Lilly (LLY) to pay more than $9B in damages to a plaintiff - Takeda is appealing the verdict - but the company has won the other five cases that have gone to trial over Actos' alleged link to bladder cancer.
- Takeda still faces claims by more than 7,000 plaintiffs.
Tue, Apr. 8, 3:07 AM
- A jury has ordered Japan's Takeda (TKPYY) to pay $6B and Eli Lilly (LLY) $3B in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.
- However, Eli Lilly could be off the hook, as Takeda agreed to indemnify Lilly for any legal liability connected to Actos.
- In addition, the award is likely to be cut on appeal, as the Supreme Court has set limits on punitive verdicts.
- In two previous cases, judges quashed multi-million dollar awards against Actos.
- Notwithstanding, Takeda's shares slumped 5.2% in Tokyo.
Tue, Feb. 4, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Dec. 27, 2013, 7:51 AM
- "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
- The drug was tied to liver damage.
- The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
- Shares fell 5%+ in Tokyo on the news.
Dec. 1, 2013, 2:50 AM
- Japan's Takeda Pharmaceutical (TKPHF) has named 20-year GlaxoSmithKline veteran Christophe Weber as the candidate to become its next CEO.
- Assuming Takeda's shareholders approve the appointment of Weber, the French national is set to become the company's first non-Japanese leader in its 232-year history.
- Weber, who is the president of GSK's vaccines division in Belgium, will become Takeda's COO by April, its president in June, and its CEO in 2015. (PR)
Jun. 10, 2013, 7:37 AMVia the European Decentralized Procedure (Netherlands is the Reference Member State), Apricus (APRI) gets its ED treatment Vitaros approved. The company believes it will "capture a significant share of the ~$1B PDE-5 inhibitor market." APRI says it will work with partners Sandoz, Takeda (TKPHF.PK), and Bracco to obtain national phase approvals. Shares +9.38% premarket. (PR) | Comment!
Mar. 19, 2013, 8:18 AMNPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR) | Comment!
Feb. 24, 2013, 3:31 AMAffymax (AFFY) and Japan's Takeda Pharmaceutical (TKPHF.PK) have voluntarily recalled all lots of anemia treatment Omontys in the U.S. following reports of "serious hypersensitivity reactions," including fatalities in "0.02%" of over 25,000 patients after an initial injection. The recall comes after Fresenius said earlier this month that it was halting a pilot program using Omontys. (PR) | 1 Comment
Jan. 7, 2013, 12:12 PMAffymax (AFFY +5.4%) and Japanese drug maker Takeda Pharmaceuticals (TKPYY.PK) have entered into a supply agreement for sourcing and supply of Omontys Injection with DSI Renal. Financial terms weren't disclosed, but the agreement allows DSI Renal to purchase the drug for use within its organization, provide discounts and rebates on the product in its selected centers, and then, based on ongoing evaluation, potentially expand to additional facilities. | Comment!
Jan. 3, 2013, 1:03 PMAffymax (AFFY +0.4%) and Takeda Pharmaceuticals (TKPYY.PK) announce that the J-code assigned by the Centers for Medicare and Medicaid Services for Omontys Injection is now effective. This permanent billing code provides streamlined reimbursement for dialysis organizations prescribing the drug for anemia in the United States. | Comment!
Sep. 25, 2012, 4:42 PMSucampo Pharmaceuticals (SCMP) and Takeda Pharmaceuticals (TKPYY.PK) say the FDA,has granted priority review of their supplemental new drug application for an additional indication for Amitiza, a treatment for opioid-induced constipation in patients with chronic, non-cancer pain. A decision is expected by late January 2013. Shares +7% AH. | Comment!
Sep. 13, 2012, 9:22 AM
Jul. 27, 2012, 4:18 PMFuriex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones. | Comment!
Jul. 2, 2012, 2:38 PMPiper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. | Comment!
Apr. 26, 2012, 8:36 AM
TKPYY vs. ETF Alternatives
Other News & PR